[go: up one dir, main page]

SG11202005850VA - Methods of treatment of hypertrigl yceridemia - Google Patents

Methods of treatment of hypertrigl yceridemia

Info

Publication number
SG11202005850VA
SG11202005850VA SG11202005850VA SG11202005850VA SG11202005850VA SG 11202005850V A SG11202005850V A SG 11202005850VA SG 11202005850V A SG11202005850V A SG 11202005850VA SG 11202005850V A SG11202005850V A SG 11202005850VA SG 11202005850V A SG11202005850V A SG 11202005850VA
Authority
SG
Singapore
Prior art keywords
yceridemia
hypertrigl
treatment
methods
hypertrigl yceridemia
Prior art date
Application number
SG11202005850VA
Inventor
Ryu Oshima
Kazuhito Suehira
Gary Gordon
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of SG11202005850VA publication Critical patent/SG11202005850VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202005850VA 2017-12-21 2018-12-20 Methods of treatment of hypertrigl yceridemia SG11202005850VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762609048P 2017-12-21 2017-12-21
PCT/US2018/066976 WO2019126597A1 (en) 2017-12-21 2018-12-20 Methods of treatment of hypertrigl yceridemia

Publications (1)

Publication Number Publication Date
SG11202005850VA true SG11202005850VA (en) 2020-07-29

Family

ID=66995099

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202005850VA SG11202005850VA (en) 2017-12-21 2018-12-20 Methods of treatment of hypertrigl yceridemia

Country Status (9)

Country Link
US (1) US20190224169A1 (en)
EP (1) EP3727376A4 (en)
JP (2) JP2021506907A (en)
CN (1) CN111741753A (en)
AU (1) AU2018393119B2 (en)
CA (1) CA3085951C (en)
MY (1) MY205171A (en)
SG (1) SG11202005850VA (en)
WO (1) WO2019126597A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250034041A (en) * 2022-07-15 2025-03-10 교와 가부시키가이샤 Blood LDL cholesterol lowering agent
WO2024167964A1 (en) * 2023-02-08 2024-08-15 Kowa Company, Ltd. Methods of treating and preventing peripheral artery disease
WO2025069226A1 (en) * 2023-09-26 2025-04-03 興和株式会社 Medicine containing pemafibrate

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA009374B1 (en) * 2003-09-03 2007-12-28 Кова Ко., Лтд. Ppar-activating compound and pharmaceutical composition containing same
TWI407955B (en) * 2007-03-29 2013-09-11 Kowa Co Prevention and/or treatment of hyperlipidemia
EP2902025B1 (en) * 2012-09-27 2019-08-07 Kowa Company Ltd. Therapeutic agent for dyslipidemia
MX2016017081A (en) * 2014-06-26 2017-05-01 Cymabay Therapeutics Inc SERIOUS HYPERTRIGLICERIDEMIA TREATMENT.
TWI691331B (en) * 2014-09-26 2020-04-21 日商興和股份有限公司 Treatment agent for dyslipidemia
RS61403B1 (en) * 2016-07-29 2021-02-26 Kowa Co Methods of preventing cardiovascular events in residual risk dyslipidemic populations

Also Published As

Publication number Publication date
CN111741753A (en) 2020-10-02
JP2021506907A (en) 2021-02-22
CA3085951A1 (en) 2019-06-27
JP2023181451A (en) 2023-12-21
US20190224169A1 (en) 2019-07-25
MY205171A (en) 2024-10-04
WO2019126597A1 (en) 2019-06-27
AU2018393119B2 (en) 2022-08-25
AU2018393119A1 (en) 2020-07-23
CA3085951C (en) 2022-10-11
EP3727376A1 (en) 2020-10-28
EP3727376A4 (en) 2021-07-21

Similar Documents

Publication Publication Date Title
ZA202006746B (en) Methods of treatment
IL269371A (en) Treatment methods
GB201701673D0 (en) Methods of well treatment
ZA201903873B (en) Methods of treating cochlear synaptopathy
GB201804514D0 (en) Treatment of pyroptosis
GB201410116D0 (en) Method of treatment
EP3684342C0 (en) Method of treatment
GB201815588D0 (en) Method of treatment
ZA201908539B (en) Method of treatment of cancer
GB201706406D0 (en) Method of treatment
IL254825A0 (en) Methods of treatment with taselisib
ZA201705847B (en) Treatment of pain
IL253028B (en) Method of treatment
GB201416832D0 (en) Methods of treatment
GB201804515D0 (en) Treatment of necroptosis
IL253847A0 (en) Methods of treating diseases
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
GB201602802D0 (en) Method of treatment
ZA201906319B (en) Methods of treating depression
GB201412010D0 (en) Treatment of hypertransaminasemia
GB201512139D0 (en) Methods of treatment
GB201720439D0 (en) Method of treatment
GB201718589D0 (en) Method of treatment
GB201801249D0 (en) Methods of treatment
HK40038038A (en) Methods of treatment of hypertrigl yceridemia